Why the study?
ST2 is associated with cardiovascular disease, but a meta-analysis of ST2 levels across different cardiovascular diseases had not yet been conducted.
Are soluble ST2 (sST2) levels significantly associated with the diagnosis of ischemic heart disease, myocardial infarction, or heart failure?
Meta-Analysis (n=2,833)
Are soluble ST2 (sST2) levels significantly associated with the diagnosis of ischemic heart disease, myocardial infarction, or heart failure?
Answers are grounded in this paper and cite their sources.
sST2 may serve as a useful auxiliary diagnostic biomarker for heart failure, but it does not significantly differentiate patients with ischemic heart disease or myocardial infarction from healthy individuals.
Biomarkers such as B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), cardiac troponin (cTn), and CK-MB contribute significantly to the diagnosis of cardiovascular disease (CVD). Recent studies have demonstrated that suppression of tumorigenicity 2 (ST2) is associated with CVD, but a meta-analysis of ST2 levels in different CVDs has yet to be conducted. Therefore, the present study aimed to investigate soluble ST2 (sST2) levels in patients with ischemic heart disease (IHD), myocardial infarction (MI), and heart failure (HF). A total of 1,425 studies were searched across four databases, of which 16 studies were included in the meta-analysis. The Newcastle–Ottawa Quality Assessment Scale (NOS) values of all 16 studies were ≥7. The meta-analysis results indicated that the sST2 level was not correlated with IHD (standard mean difference [SMD] = 0.58, 95% confidence interval [95% CI] = 0.00 to 1.16, p = 0.05) or MI (weighted mean difference [WMD] = 0.17, 95% CI = −0.22 to 0.55, p = 0.40) but was significantly associated with HF (WMD = 0.21, 95% CI = 0.04 to 0.38, p = 0.02; I 2 = 99%, p < 0.00001). sST2 levels did not differ significantly between patients with IHD or MI and healthy individuals; however, we believe that ST2 could be used as an auxiliary diagnostic biomarker of HF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) conducted a meta-analysis in Cardiovascular Diseases (Ischemic Heart Disease, Myocardial Infarction, Heart Failure) (n=2,833). Serum sST2 levels vs. Healthy individuals was evaluated on Serum sST2 levels in Heart Failure vs healthy individuals (WMD 0.21, 95% CI 0.04-0.38, p=0.02).
Synapse has enriched 10 related papers. Consider them for comparative context: